FDA Approved: XALKORI — Original Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

The FDA granted original approval of XALKORI (crizotinib) for patients with ALK-positive non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

ORIG AP for XALKORI (CRIZOTINIB)